Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris International’s Zyn to help adult smokers cut back or quit cigarettes.

The Food and Drug Administration (FDA) announced on Thursday that it authorized the marketing of Zyn nicotine pouches but will be "closely monitoring youth use." Newsweek reached out to Zyn for comment.

The U.S. Food and Drug Administration on Thursday okayed the marketing of 20 Zyn nicotine pouch products after undertaking an extensive scientific review of them.

The pouches are used by less than 2% of US teens, the FDA said in granting the application allowing them to continue to be sold.

The proposal in the waning days of the Biden administration leaves it up to President-elect Donald Trump to finalize the effort — or scrap it.

The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an "extensive scientific review" about their safety.

Marketing for the popular nicotine pouch product, Zyn, has been approved by the U.S. Food and Drug Administration to help smokers quit cigarettes and other tobacco products.

The U.S. Food and Drug Administration (FDA), which regulates products containing nicotine, a highly addictive drug, first raised the idea of such a cap in 2018. It said this would save lives by preventing smoking-related disease and death, by taking away the chemical that keeps smokers hooked.

FDA authorizes Zyn nicotine pouches, citing public health benefits for adult smokers, despite concerns over flavored products' appeal to teens.

The FDA authorized the marketing of 20 Zyn products on Thursday, marking the first allowance for the fast-growing nicotine pouches.

The FDA announced it has authorized the marketing of 20 Zyn nicotine pouch products, citing their greater health benefits vs. cigarettes and other tobacco products. It is the first time the agency has authorized the sale of nicotine pouches,